Chronic Lymphocytic Leukemia Clinical Trials in Los Angeles, California

7 studies are recruiting for chronic lymphocytic leukemia in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

   This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymph…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

   Locations

   632 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04269902 on ClinicalTrials.gov

2. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

   The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UCLA Department of Medicine Hematologyoncology, Los Angeles, California

   Locations

   130 in total

   Run by

   BeOne Medicines

   See if you can join NCT06846671 on ClinicalTrials.gov

3. A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

   The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UCLA Department of Medicine Hematologyoncology, Los Angeles, California

   Locations

   214 in total

   Run by

   BeOne Medicines

   See if you can join NCT06973187 on ClinicalTrials.gov

4. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

   This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhi…

   Stage

   Phase 3

   Ages

   65 and older

   Site

   Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

   Locations

   210 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT07321652 on ClinicalTrials.gov

5. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

   This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

   Stage

   Phase 1

   Ages

   13 to 90

   Site

   Valkyrie Clinical Trials, Los Angeles, California

   Locations

   11 in total

   Run by

   Vironexis Biotherapeutics Inc.

   See if you can join NCT06533579 on ClinicalTrials.gov

6. A Long-term Extension Study of PCI-32765 (Ibrutinib)

   The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California Los Angeles, Los Angeles, California

   Locations

   175 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT01804686 on ClinicalTrials.gov

7. A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

   Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetocl…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Valkyrie Clinical Trials /ID# 268151, Los Angeles, California

   Locations

   70 in total

   Run by

   AbbVie

   See if you can join NCT06428019 on ClinicalTrials.gov